Share article:
Share article:

How a vaccine developed so quickly can still be safe

Credit: Belga

The rapid development of a coronavirus vaccine does not mean there is any inherent risk, and proper policy has been followed, according to Belgian health experts.

Facing several months focused on the Covid-19 vaccines and their administration,  officials explained why – despite the accelerated development – they will be safe for use.

“If all goes well, the vaccines against the coronavirus, or at least some of them, will be developed and registered within only a year,” said virologist and interfederal Covid-19 spokesperson Steven Van Gucht.

While it usually to seven to eight years before a vaccine or medicine was declared ready for use in the past, these vaccines must still meet the same safety requirements as other medicines.

“Just like so many pills or capsules we take so often,” he said, adding that “no health authority in Western society” has taken even the slightest risk.

Advanced technology

When the virus had only just been discovered at the beginning of January, it was possible to determine its genetic composition in just a few days, thanks to enormous advances in technology.

“As a reminder, the outbreak with a then-unknown virus was first reported on 31 December in Wuhan,” Van Gucht said. “Nearly 10 days later, on 10 January, the full genetic code of the coronavirus was known and published.”

It was made public, and distributed all over the world so that laboratories across the globe could start research into a vaccine very early on, according to him.

Not starting from scratch

Additionally, researchers did not have to start from scratch, as two dangerous coronaviruses were already known to them.

“Namely the coronavirus that caused SARS in 2003, and another coronavirus that has been causing MERS in the Middle East since 2012,” Van Gucht said.

“Vaccines were already being developed against these two known coronaviruses, and they could be adapted to (also) be effective against this new coronavirus,” he said, adding that the same happened with vaccines which were initially intended against the Ebola virus.

Related News:

 

Rolling review

“Additionally, research on the coronavirus vaccine has been given priority over many other projects over the past year,” Van Gucht said, adding that this happened in close cooperation with registration authorities around the world, such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).

Normally, three clinical stages are carried out one after the other in these studies. “But here, time was gained by partially overlapping the three phases,” he said.

This ‘rolling review’ system has made it possible to analyse an enormous amount of data on the efficacy and safety of these vaccines in a short space of time, both at company and government level.

“The data from these clinical trials have been assessed on an ongoing basis by independent bodies, rather than just once at the end,” Van Gucht said.

Early investment

On top of that, governments, as well as the European Commission, joined forces to invest in production facilities long before the vaccines were authorised.

“This entails a great risk, and that risk still exists: that for many of these companies, the investment could be completely lost if the candidate vaccine were to prove ineffective, or unsafe, and ultimately not approved by the authorities,” Van Gucht stressed.

On the other hand, he clarified, this was the only way to have enough vaccines ready to launch a vaccination campaign in the days and weeks after obtaining marketing authorisation.

Large clinical trials

“By reviewing the scientific literature of the last 50 years, the American agencies have found that almost all vaccine side effects occur within a few days after administration, up to six weeks after administration,” Van Gucht said.

Based on that information, vaccination registration dossiers, both in Europe and the US, could only be submitted after the volunteers had been followed up for at least eight weeks.

“An additional two weeks were therefore already taken as an additional precaution,” he said.

Van Gucht stressed that the newly developed coronavirus vaccines were tested in large clinical trials, in which larger groups than usual were vaccinated.

However, almost all people will still experience some minor side effects from being vaccinated, such as a slight headache, some fatigue, or even a slight increase in body temperature.

“These are mild effects, which will pass. And they usually mean that the vaccine does its job properly,” Van Gucht said. “2020 was the year of the virus, let us hope that 2021 will be the year of the vaccine.”

Maïthé Chini
The Brussels Times

Latest news

‘No scientific basis’ for giving everyone third dose, vaccine expert says
The head of Belgium's Vaccination Taskforce has argued that there is not enough scientific evidence to support the Flemish government's decision to ...
Re-introducing face masks indoors considered as Covid-19 situation worsens
Belgium's council of ministers will hold an emergency meeting on Monday to discuss the worsening epidemiological situation, and reintroducing face ...
Threats of strike action could affect Brussels’ STIB network from Monday
Brussels public transport operator STIB's trams, buses and metros could be affected from Monday 25 October onwards as the union representing the ...
Brussels bars linked to alleged sexual assault vouch to improve women’s safety
The management of the two bars in Ixelles, which made headlines in recent days after several young women reported that they had been drugged then ...
European Council: Decisions on Covid-19 and energy and debate on other issues
At the two-days summit which ended on Friday, the European Council adopted conclusions on COVID-19, digital, energy prices, migration, trade and ...
Flanders ‘water bomb’ could cause €2 billion in damages and affect thousands
The next "water bomb" or heavy rainfall over Flanders could cause damages estimated at around €2 billion, and could affect up to 100,000 people in ...
Pfizer Covid-19 vaccine 90% effective in 5 to 11-year-olds
The Pfizer-BioNTech vaccine is 90.7% effective in preventing symptomatic forms of the coronavirus in children aged five to 11, Pfizer announced on ...
Belgian airport named best for cargo in Europe
Brussels Airport has been named the best airport in Europe in a 2021 roundup of the best cargo airports across the world. The Asian Freight, ...
NASA plans first return mission to Moon in February 2022
The United States space agency, NASA, has announced that it will be aiming to launch its first, uncrewed mission to the moon, Artemis 1, in February ...
New, reportedly more contagious Delta mutation being monitored
A new mutation of the Delta variant of the coronavirus, which is reported to be more contagious, is being monitored by health authorities in the ...
Angèle releases new single: ‘Bruxelles je t’aime’
Belgian singer Angèle has unveiled her latest song ahead of the release of her new album, due later this year. 'Bruxelles je t'aime' (Brussels I ...
23 million chickens and 1.7 million pigs: Climate experts call for livestock cut
Flander's livestock needs to be drastically cut to save the climate and reach the emission reduction targets, according to the latest advice from the ...